NCT00256230View on ClinicalTrials.gov

Disulfiram in Patients With Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Stage IV Melanoma
Interventions
DRUG

Disulfiram (DSF)

DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

John P. Fruehauf

OTHER

NCT00256230 - Disulfiram in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter